OverviewSuggest Edit

Immunovia engages in the development of a technology platform based on antibody microarray analysis. It focuses on developing diagnosis of cancer and autoimmune diseases. The Company offers IMMray PanCan-d, a blood-based test for the detection of pancreatic cancer. It also provides IMMray Proteome Survey platform, a discovery tool for proteome scanning. 

TypePublic
Founded2007
HQLund, SE
Websiteimmunovia.com

Latest Updates

Employees (est.) (Sept 2020)59(+41%)
Share Price (Sept 2020)KR202 (+2%)
Cybersecurity ratingAMore

Key People/Management at Immunovia

Rolf Ehrnström

Rolf Ehrnström

Chief Scientific Officer
Mimmi Ekberg

Mimmi Ekberg

Director
Carl Borrebaeck

Carl Borrebaeck

Chairman of the Board
Mats Grahn

Mats Grahn

CEO
Hans Liljenborg

Hans Liljenborg

Chief Financial Officer
Laura Chirica

Laura Chirica

Chief Commercial Officer
Show more

Immunovia Office Locations

Immunovia has offices in Lund, Marlborough and Frankfurt am Main
Lund, SE (HQ)
Medicon Village Scheelevägen 2
Frankfurt am Main, DE
Herriotstraße 1
Marlborough, US
26 Forest St #110, Marlborough
Show all (3)

Immunovia Financials and Metrics

Immunovia Revenue

Market capitalization (16-Sept-2020)

4.6b

Closing stock price (16-Sept-2020)

202.0
Immunovia's current market capitalization is kr4.6 b.
Show all financial metrics

Immunovia Cybersecurity Score

Cybersecurity ratingPremium dataset

A

91/100

SecurityScorecard logo

Immunovia Online and Social Media Presence

Embed Graph

Immunovia News and Updates

Immunovia Announces Management Team Changes

LUND, Sweden, Sept. 2, 2020 /PRNewswire/ -- Immunovia AB (publ) ("Immunovia") a near-commercial stage diagnostics company developing ground-breaking antibody-based multiplex microarray technology platform called IMMray™ for the early detection of cancer, announced today that Dr. Peter...

Notice of Extraordinary General Meeting in Immunovia AB

STOCKHOLM, Aug. 31, 2020 /PRNewswire/ -- The Board of Directors of Immunovia AB (publ), corporate identity number 556730-4299, hereby convenes an Extraordinary General Meeting on Wednesday, September 23, 2020, at 16.00 in The Spark, Scheeletorget 1, Medicon Village, Lund. Due to the...

Immunovia Announces CEO Transition: Appoints Patrik Dahlen as New CEO

LUND, Sweden , Aug. 26, 2020 /PRNewswire/ -- Immunovia AB (publ) ("Immunovia"), today announced that the Board of Directors has appointed Patrik Dahlen as new CEO starting November 1, 2020. Patrik Dahlen has extensive experience as previous CEO of several diagnostic companies and succeeds...

Immunovia Reports Second Quarter Interim Report January - June 2020

LUND, Sweden, Aug. 20, 2020 /PRNewswire/ -- Immunovia has today published second quarter interim report for January - June 2020. It is available on Immunovia's website. "During Q2, we successfully handled COVID-19 challenges beyond our control, strengthened the company's economic...

Immunovia to Host a Second Webinar in the Series on IMMray™ PanCan-d: Commercial Test Model Study & Update on Launch Activities

LUND, Sweden, Aug. 18, 2020 /PRNewswire/ -- Immunovia AB (publ) ("Immunovia"), today announced that the company will be hosting the second webinar in the series on Immunovia's IMMray™ PanCan-d. This second webinar will cover the results of the Commercial Test Model Study (link to pr) and...

Change in the Number of Shares and Votes in Immunovia AB (publ)

LUND, Sweden, June 30, 2020 /PRNewswire/ -- Immunovia AB (publ) ("Immunovia") today announced that the number of shares and votes in Immunovia has changed due to the fact that shares have been registered after the directed share issue which was carried out in June 2020. Through the...
Show more

Immunovia Blogs

In 2018, Immunovia reached over 24,000 people through 24 Walks in 15 US states

Beginning in April 2018, Immunovia partnered with several prominent patient organizations by sponsoring pancreatic cancer walks across the United States. Organized nationally throughout the year, these walks increase awareness about the disease and raise money for research. The walks also allow peop…

Nobel Laureates’ visit has special significance for Immunovia

Following the official ceremony in Stockholm, the shared winners of this year’s Nobel Prize in Chemistry, George P. Smith and Sir Gregory P. Winter, visited Medicon Valley to give inspiring presentations on their pioneering work in developing ways of producing human antibodies, the proteins produced…

Year End message from Immunovia´s CEO Mats Grahn

As the snow falls over Immunovia’s facilities in Lund, Sweden and Marlborough, USA, season’s greetings from all of us! We’d like to invite all of our investors, collaborators, supporters and suppliers to join in celebrating what has been a year of great progress. Over the last year, we have continue…

Allbright Foundation’s green list of Swedish companies promotes Immunovia for gender equality

A recent report published by the Allbright Foundation has shown that the gender balance in Swedish corporations is moving towards more equality, but large differences between companies still exist. Out of the 329 listed companies, 28 have female CEOs, 65% up since last year’s report. Furthermore, eq…

In a major drive to raise awareness about signs, symptoms and risk factors for pancreatic cancer, over 70 Boston-area primary care clinicians attended Immunovia´s educational symposium at Fenway Park, on World Pancreatic Cancer Day 2018

On November 15, 2018, Immunovia, Inc. sponsored an educational symposium at Fenway Park in honor of World Pancreatic Cancer Day, a day when people across the globe work together to increase awareness of the signs and symptoms of pancreatic cancer. Immunovia’s goal for the day was to increase awarene…

Immunovia facility expansion

Today, on World Pancreatic Cancer Day November 15 2018, we are delighted to share with you some exciting news about Immunovia. The company is growing and is expanding its facility in Lund, Sweden. In preparation for commercialising IMMray™ PanCan-d for the early detection of pancreatic cancer, Immun…
Show more

Immunovia Frequently Asked Questions

  • When was Immunovia founded?

    Immunovia was founded in 2007.

  • Who are Immunovia key executives?

    Immunovia's key executives are Rolf Ehrnström, Mimmi Ekberg and Carl Borrebaeck.

  • How many employees does Immunovia have?

    Immunovia has 59 employees.

  • Who are Immunovia competitors?

    Competitors of Immunovia include Prime Genomics, Predicine and Capio Biosciences.

  • Where is Immunovia headquarters?

    Immunovia headquarters is located at Medicon Village Scheelevägen 2, Lund.

  • Where are Immunovia offices?

    Immunovia has offices in Lund, Marlborough and Frankfurt am Main.

  • How many offices does Immunovia have?

    Immunovia has 3 offices.